Abstract:The BROADEN study is one of the largest observational studies conducted in Japan assessing human papilloma virus (HPV) in head and neck cancer (HNC). The study includes 1108 patients diagnosed in 2008–2009 and 2018–2019 across 19 hospitals. Overall 981 HNC samples were tested by HPV‐DNA PCR, p16INK4a, and HPV E6*I mRNA in a central laboratory using strict quality control processes for all laboratory steps. This study demonstrates an increasing trend of HPV attributability in oropharyngeal cancer over this 10‐year period, from 44.2% in 2008–2009 to 51.7% in 2018–2019 reflecting an annual percentage change (APC) of 1.58%, as well as in nasopharyngeal cancers from 3.2% to 7.5% representing an APC of 8.92%. Men accounted for 82% of HNC diagnoses, and patients in the earlier cohort were younger and had a higher percentage of smokers. Notably, the study found that 94.6% of these HPV‐driven HNC cases were attributed to HPV genotypes included in the prophylactic 9‐valent HPV vaccine highlighting the value of potential preventive strategies. There is limited understanding of epidemiology and time trends of human papilloma virus (HPV)‐driven head and neck cancers (HNC) in Japan, especially outside of the oropharynx. To assess HPV‐driven HNC, a non‐interventional study (BROADEN) of HNC patients diagnosed in 2008–2009 and 2018–2019 was conducted in Japan. Adult patients with oropharyngeal, nasopharyngeal, laryngeal, hypopharyngeal or oral cavity cancers were included in this study. HPV was centrally tested using p16INK4a immunohistochemistry, HPV‐DNA PCR and HPV E6*I mRNA. HPV attributability required positivity in at least two tests (p16INK4a immunohistochemistry, HPV‐DNA PCR, HPV E6*I mRNA) in the oropharynx, and HPV‐DNA and HPV E6*I mRNA positivity for non‐oropharynx sites. Nineteen hospitals included a total of 1108 patients, of whom 981 had valid samples. Men accounted for 82% of HNC diagnoses. Patients in the earlier cohort were younger and included a higher percentage of smokers. There was an increasing trend of HPV‐driven oropharyngeal cancer over the last decade, from 44.2% to 51.7%. HPV attribution in nasopharyngeal cancers was 3.2% in 2008–2009 and 7.5% in 2018–2019; and 4.4% and 0% for larynx respectively. In total, 95.2% of HPV‐driven HNC were attributed to HPV genotypes included in the 9‐valent HPV vaccine being HPV16 the most prominent genotype. These results suggest that an epidemiologic shift is happening in Japan, with a decrease in smoking and alcohol use and an increase in HPV‐driven HNC. The increasing trend of HPV‐driven HNC in Japan highlights the need for preventive strategies to mitigate the rise of HPV‐driven HNC.

Role of automated measurements in understanding lifestyle effects on blood pressure.

Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry

Definitive radiotherapy for nasopharyngeal carcinoma in Japan: analysis of cases in the National Head and Neck Cancer Registry from 2011 to 2014

Analysis of prognostic factors through survival rate analysis of oral squamous cell carcinoma patients treated at the National Cancer Center: 20 years of experience

Incidence, prevalence, and survival of head and neck cancers in the United Kingdom from 2000-2021

Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study

A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry

Report of the 20th Nationwide follow‐up survey of primary liver cancer in Japan

Trends in patterns of treatment and survival of colorectal cancer patients using cancer registry data in Japan: 1995–2015

Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data

Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization.

Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)

Herbal Remedy : An Alternate Therapy of Nonsteroidal Anti-Inflammatory Drug Induced Gastric Ulcer Healing

Report of the 23rd Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan (2014–2015)

Predictors of recurrence and survival after salivary gland cancer surgery: A multicenter, retrospective study in northern Japan

Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry

The impact of COVID-19 pandemic on head and neck cancer diagnosis and treatment

Human papillomavirus‐driven head and neck cancers in Japan during 2008–2009 and 2018–2019: The BROADEN study

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048

Prevalence of survivors of childhood cancer based on a population‐based cancer registry in Osaka, Japan

Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)